Dasatinib in Treating Patients With Stage IV Pancreatic Cancer
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth.
PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with
stage IV pancreatic cancer.